The influence of somatostatin/octreotide treatment on outcomes of neonates with congenital chylothorax remains controversial. We retrospectively reviewed our experience with somatostatin/octreotide therapy in neonates with this very rare disease. Fourteen neonates with congenital chylothorax who were treated with somatostatin (3.5–7 μg/kg/h, before 2016) or octreotide (1–6 μg/kg/h, after January 2016), along with traditional management between 2013 and 2016, were retrospectively reviewed in this observational study. Their daily volumes of pleural drainage and parameters of respiratory support were recorded, and the potential side effects of somatostatin/octreotide were screened. Four patients (28.6%) had a unilateral presentation of pleural effusion, whereas 10 patients (71.4%) had a bilateral presentation. Twelve patients (85.7%) survived until discharge without later recurrence or death, whereas 2 patients (14.3%) died within the first 3 days after birth. Somatostatin/octreotide treatment was maintained for a median period of 6 days (range 1–16 days). The chest tube was removed after a median duration of 14 days (range 2–51 days), and no patient needed pleurodesis or thoracic duct ligation surgery. The average daily drain output within 3 days post-treatment (median 62 mL, range 10–651 mL) was significantly lower than that before treatment (median 133 mL, range 70–620 mL) (P = .002). The need for ventilation support was reduced in most patients (85.7%) after the initiation of somatostatin/octreotide therapy. No serious side effects were identified. Somatostatin/octreotide treatment reduced pleural drainage and respiratory support without significant side effects. Further randomized controlled studies with more patients are necessary to ascertain the benefits of somatostatin/octreotide in neonates with congenital chylothorax.
1 March 2015 in American Journal of Infection Control
This study aimed to determine the cause behind the outbreak of nosocomial adenoviral conjunctivitis in the Neonatal Intensive Care Unit (NICU) and the impact of infection control measures. The objectives of the present study include investigation of the hospital-borne infection associated with adenoviral conjunctivitis, analysis of the possible risk factors, setting bundle infection control measures, which were adjusted according to the control effect. The present study also aims to observe the effect of different intervention measures on controlling adenoviral conjunctivitis. During the first and second intervention periods, overall 635 and 597 NICU patients were enrolled, respectively. Ophthalmoscopy was conducted among 188 (in the first intervention) and 184 (in the second intervention) patients (P>0.05). The times of ophthalmoscopy the patients received were 417 and 457 (P<0.001). During the first intervention, 13 patients suffered from adenoviral conjunctivitis, while no patients with adenoviral conjunctivitis were found during the second intervention (P<0.001). All adenoviral conjunctivitis cases were reported 6-27 days (mean 12 days) after ophthalmoscopy. The hydrogen peroxide disinfection bundle measures can effectively restrict the prevalence of adenoviral conjunctivitis associated with ophthalmoscopy in premature infants.